Invest in us
We highly value our investors who are supporting us on our journey. Your investment helps drive earlier, more accurate diagnoses, reducing unnecessary procedures and improving patient outcomes. Together, we are empowering healthcare professionals and saving lives.
We are actively seeking partnerships and funding to help us bring this solution to healthcare providers around the world. Join us in building the future of women's health.
“This solution has tremendous potential to save lives, especially in places where specialists in obstetrics and gynecology are few in relation to urgent needs. The team of researchers and developers at Intelligyn is most impressive and convinced us to invest earlier than we normally would”
Ruth Brännvall, Investor
Investor FAQs
-
The market potential for IntelligynAI is significant, considering the high prevalence of ovarian tumors among women worldwide. Our platform addresses a critical need for accurate and efficient diagnostic support, making it an attractive investment opportunity.
-
IntelligynAI is currently at Technology Readiness Level (TRL) 5, with a working prototype being tested in clinical usability studies at Södersjukhuset, a major university hospital in Stockholm, Sweden. We are continuously refining our platform based on user feedback and research. We are working with our notified body to achieve regulatory certification.
-
Our primary revenue streams include licensing fees for healthcare providers and institutions using IntelligynAI, as well as potential partnerships with medical device manufacturers for seamless integration with their ultrasound systems.
-
As with any investment, there are inherent risks involved. These include regulatory challenges, competition from other diagnostic tools, and potential technological setbacks. However, we are committed to mitigating these risks through ongoing research, partnerships, and adherence to industry standards.
-
Our long-term vision is to become the go-to platform for accurate and reliable diagnostic support in women’s healthcare, expanding beyond ovarian tumor evaluation. We aim to achieve this through continuous technological advancements, strategic partnerships, and global market expansion.